NCT06014502View on ClinicalTrials.gov

Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

September 7, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Solid Tumor
Interventions
DRUG

IMGS-001

Every 2 weeks

Trial Locations (5)

70121

RECRUITING

Ochsner Clinic Foundation, New Orleans

75039

RECRUITING

NEXT Dallas, Irving

77030

RECRUITING

MD Anderson Cancer Center, Houston

85234

RECRUITING

Banner MD Anderson Cancer Center, Gilbert

90403

RECRUITING

Sarcoma Oncology Center, Santa Monica

Sponsors

Lead Sponsor

ImmunoGenesis
All Listed Sponsors
lead

ImmunoGenesis

INDUSTRY

NCT06014502 - Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | Biotech Hunter | Biotech Hunter